An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer

Authors
Publication date
11 May 2018
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Debrecen Electronic Archive

    redirect
    oaioai:dea.lib.unideb.hu:2437/248...
    Last time updated on 12/09/2018